BACKGROUND Biologics are used for the treatment of inflammatory bowel diseases, Crohn´s disease and ulcerative colitis refractory to conventional treatment. In order to allocate healthcare spending efficiently, costly biologics for inflammatory bowel diseases are an important target for cost-effectiveness analyses. The aim of this study was to systemically review all published literature on the...

Background Biologics have gained traction for use in oncology, but have demonstrate clinical variability for efficacy and safety. Therapeutic drug monitoring (TDM) can benefit patients' outcomes from a biologic therapy when the latter has a defined therapeutic window. A clinically relevant therapeutic window may exist for biologics with established exposure-response (E-R) relationships for effi...

BACKGROUND Several biologic medicines are available to treat rheumatoid arthritis (RA), and they differ in administration method (subcutaneous or intravenous [IV]). We analyzed a pharmacy benefit manager database to estimate claims-based, algorithm-determined effectiveness and cost per effectively treated patient for biologics used to treat RA. METHODS We analyzed the Medco Health Solutions p...

Australasian Journal of DermatologyVolume 64, Issue S1 p. 15-30 ABSTRACT Biologics/Psoriasis First published: 22 May 2023 https://doi.org/10.1111/ajd.14037Read the full textAboutPDF ToolsRequest permissionExport citationAdd to favoritesTrack citation ShareShare Give accessShare text full-text accessPlease review our Terms and Conditions Use check box below share version article.I have read acce...

The growing ubiquity of electronic devices is increasingly consuming substantial energy and rare resources for materials fabrication, as well as creating expansive volumes of toxic waste. This is not sustainable. Electronic biological materials (e-biologics) that are produced with microbes, or designed with microbial components as the guide for synthesis, are a potential green solution. Some e-...

Pyoderma gangrenosum (PG) is an uncommon extra-intestinal manifestation of inflammatory bowel disease (IBD). Despite limited published literature, biologics have caused a paradigm shift in the management of this difficult-to-treat skin condition. The clinical data and outcomes of three patients with active ulcerative colitis and concurrent PG treated with biologics (infliximab two and adalimuma...

Introduction In the past decade biologics have changed the management of juvenile idiopathic arthritis (JIA). Many studies have evaluated the effectiveness and safety of the available biologics in JIA. Biological therapy used to be reserved for the severely ill JIA patients refractory to conventional therapy. Due to the treatment success of several biologics, more and more patients with JIA are...

Contact Information: Andrew Shim, PharmD, JD, MAM; email: [email protected] Among insured patients, out-of-pocket costs for biologics may be high. Previous research suggests higher cost-sharing for biologics is associated with higher rates of abandonment (failure to pick up a filled prescription at the pharmacy). Higher out-of-pocket costs also may affect medication persistency (continuat...

The efficacy of biologic or conventional systemic therapies for psoriasis has been shown in randomized controlled trials. Effectiveness, however, has been studied in daily practice cohorts, and no aggregation of effectiveness data is available. This systematic review searched PubMed and EMBASE and summarized the real-world evidence on effectiveness of biologics (adalimumab, etanercept, inflixim...

Immune responses to some monoclonal antibodies (mAbs) and biologic proteins interfere with their efficacy due to the development of anti-drug antibodies (ADA). In the case of mAbs, most ADA target 'foreign' sequences present in the complementarity determining regions (CDRs). Humanization of the mAb sequence is one approach that has been used to render biologics less foreign to the human immune ...